

Jim C Oates

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4993596/publications.pdf>

Version: 2024-02-01

82
papers

2,482
citations

182225

30
h-index

242451

47
g-index

83
all docs

83
docs citations

83
times ranked

3308
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing and Validating Methods to Assemble Systemic Lupus Erythematosus Births in the Electronic Health Record. <i>Arthritis Care and Research</i> , 2022, 74, 849-857.	1.5	10
2	Upregulated Interleukin-10 Induced by E2F Transcription Factor 2 MicroRNA Circuitry in Extrafollicular Effector B Cells Contributes to Autoantibody Production in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 496-507.	2.9	12
3	Prediction models of treatment response in lupus nephritis. <i>Kidney International</i> , 2022, 101, 379-389.	2.6	18
4	RAS-mediated nitric oxide signaling in podocytes. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
5	Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases. <i>American Journal of the Medical Sciences</i> , 2021, 361, 169-175.	0.4	6
6	The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients. <i>Lupus Science and Medicine</i> , 2021, 8, e000482.	1.1	6
7	Camptothecin and Topotecan, Inhibitors of Transcription Factor Fl-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. <i>Arthritis and Rheumatology</i> , 2021, 73, 1478-1488.	2.9	17
8	Plasma Sphingolipid Profile Associated With Subclinical Atherosclerosis and Clinical Disease Markers of Systemic Lupus Erythematosus: Potential Predictive Value. <i>Frontiers in Immunology</i> , 2021, 12, 694318.	2.2	13
9	Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis. <i>Lupus Science and Medicine</i> , 2021, 8, e000489.	1.1	13
10	Support Methodologies for African American Women With Lupus – Comparing Three Methods™ Effects on Patient Activation and Coping. <i>Frontiers in Psychology</i> , 2021, 12, 734390.	1.1	3
11	1103...Perfluoroalkyl substances and community vulnerability: associations with lupus-related autoantibodies and disease. , 2021, , .		0
12	The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus. <i>Healthcare (Switzerland)</i> , 2021, 9, 1507.	1.0	2
13	Variable selection methods for identifying predictor interactions in data with repeatedly measured binary outcomes. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e59.	0.3	0
14	Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells. <i>Lupus Science and Medicine</i> , 2020, 7, e000418.	1.1	7
15	2020 Southern Society for Clinical Investigation Founders™ Medal Award. <i>American Journal of the Medical Sciences</i> , 2020, 360, 83-84.	0.4	0
16	Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery in Clinic. <i>Frontiers in Microbiology</i> , 2020, 11, 613268.	1.5	12
17	ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Transactions of the American Clinical and Climatological Association</i> , 2020, 131, 157-177.	0.9	2
18	Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 529.	0.7	13

#	ARTICLE	IF	CITATIONS
19	Progesterone decreases gut permeability through upregulating occludin expression in primary human gut tissues and Caco-2 cells. <i>Scientific Reports</i> , 2019, 9, 8367.	1.6	49
20	A Link Between Plasma Microbial Translocation, Microbiome, and Autoantibody Development in First-Degree Relatives of Systemic Lupus Erythematosus Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1858-1868.	2.9	71
21	L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells. <i>Lupus Science and Medicine</i> , 2019, 6, e000294.	1.1	6
22	Tissue Damage in Lupus. , 2019, , 248-260.		0
23	“We Would Still Find Things to Talk About” Assessment of Mentor Perspectives in a Systemic Lupus Erythematosus Intervention to Improve Disease Self-Management, Empowering SLE Patients. <i>Journal of the National Medical Association</i> , 2018, 110, 182-189.	0.6	6
24	Peer-to-Peer Mentoring for African American Women With Lupus: A Feasibility Pilot. <i>Arthritis Care and Research</i> , 2018, 70, 908-917.	1.5	26
25	Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. <i>American Journal of the Medical Sciences</i> , 2018, 355, 293-298.	0.4	20
26	Research participation preferences as expressed through a patient portal: implications of demographic characteristics. <i>JAMIA Open</i> , 2018, 1, 202-209.	1.0	18
27	The association between method of solicitation and patient permissions for use of surplus tissues and contact for future research. <i>JAMIA Open</i> , 2018, 1, 195-201.	1.0	2
28	My life with lupus: contextual responses of African-American women with systemic lupus participating in a peer mentoring intervention to improve disease self-management. <i>BMJ Open</i> , 2018, 8, e022701.	0.8	7
29	The SLE-key test serological signature: new insights into the course of lupus. <i>Rheumatology</i> , 2018, 57, 1632-1640.	0.9	9
30	Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. <i>American Journal of the Medical Sciences</i> , 2017, 353, 580-592.	0.4	22
31	Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. <i>Human Immunology</i> , 2017, 78, 574-581.	1.2	10
32	IFN- γ Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2017, 199, 1979-1988.	0.4	57
33	A population-based approach for implementing change from opt-out to opt-in research permissions. <i>PLoS ONE</i> , 2017, 12, e0168223.	1.1	19
34	Reactive Nitrogen Intermediates in the Pathogenesis of Systemic Lupus Erythematosus. , 2016, , 243-253.		0
35	Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016, 68, 1866-1873.	1.5	61
36	Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1955-1963.	2.9	42

#	ARTICLE	IF	CITATIONS
37	Presentation of the 2016 Founders™ Medal Award. American Journal of the Medical Sciences, 2016, 352, 6-8.	0.4	1
38	At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. Journal of Leukocyte Biology, 2016, 99, 265-278.	1.5	144
39	SLE-key® rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP®. Journal of Immunological Methods, 2016, 429, 1-6.	0.6	18
40	Renal Glycosphingolipid Metabolism Is Dysfunctional in Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1402-1413.	3.0	63
41	A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients. American Journal of the Medical Sciences, 2015, 350, 302-307.	0.4	25
42	Endothelial Dysfunction in Injury and Inflammation. American Journal of the Medical Sciences, 2015, 349, 2.	0.4	4
43	Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1 α and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway. Free Radical Biology and Medicine, 2015, 84, 185-195.	1.3	11
44	Improving clinical trial accrual by streamlining the referral process. International Journal of Medical Informatics, 2015, 84, 15-23.	1.6	13
45	Role of Interferon Alpha in Endothelial Dysfunction: Insights Into Endothelial Nitric Oxide Synthase-Related Mechanisms. American Journal of the Medical Sciences, 2014, 348, 168-175.	0.4	19
46	A Critical Role of the Transcription Factor Flt-1 in Murine Lupus Development by Regulation of Interleukin-6 Expression. Arthritis and Rheumatology, 2014, 66, 3436-3444.	2.9	34
47	Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry. Journal of Rheumatology, 2013, 40, 842-849.	1.0	15
48	NADPH oxidase and nitric oxide synthase-dependent superoxide production is increased in proliferative lupus nephritis. Lupus, 2013, 22, 1361-1370.	0.8	13
49	The Magic of the Southern Society for Clinical Investigation: Can We Make the Vanishing Physician-Scientist Reappear?. American Journal of the Medical Sciences, 2013, 345, 259.	0.4	1
50	Inhibition of Sphingosine Kinase-2 in a Murine Model of Lupus Nephritis. PLoS ONE, 2013, 8, e53521.	1.1	34
51	Endothelial Nitric Oxide Synthase Reduces Crescentic and Necrotic Glomerular Lesions, Reactive Oxygen Production, and MCP1 Production in Murine Lupus Nephritis. PLoS ONE, 2013, 8, e64650.	1.1	33
52	Overcoming the Effects of Matrix Interference in the Measurement of Urine Protein Analytes. Biomarker Insights, 2012, 7, BMI.S8703.	1.0	34
53	Premature Atherosclerosis Is Associated With Hypovitaminosis D and Angiotensin-Converting Enzyme Inhibitor Non-use in Lupus Patients. American Journal of the Medical Sciences, 2012, 344, 268-273.	0.4	60
54	Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus. Cellular Immunology, 2012, 276, 42-51.	1.4	20

#	ARTICLE	IF	CITATIONS
55	The Role of Reactive Nitrogen and Oxygen Intermediates in Systemic Lupus Erythematosus. , 2011, , 199-211.		3
56	Selective Cyclooxygenase-2 Inhibitor Suppresses Renal Thromboxane Production but Not Proliferative Lesions in the MRL/lpr Murine Model of Lupus Nephritis. American Journal of the Medical Sciences, 2011, 341, 101-105.	0.4	2
57	Upregulation of xCT by KSHV-Encoded microRNAs Facilitates KSHV Dissemination and Persistence in an Environment of Oxidative Stress. PLoS Pathogens, 2010, 6, e1000742.	2.1	98
58	Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Annals of the Rheumatic Diseases, 2010, 69, 1220-1226.	0.5	58
59	The biology of reactive intermediates in systemic lupus erythematosus. Autoimmunity, 2010, 43, 56-63.	1.2	41
60	The Place of William Osler in the Description of Systemic Lupus Erythematosus. American Journal of the Medical Sciences, 2009, 338, 409-412.	0.4	11
61	Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. Arthritis and Rheumatism, 2008, 58, 263-272.	6.7	51
62	Rituximab-responsive Cryoglobulinemic Glomerulonephritis in a Patient With Autoimmune Hepatitis. Journal of Clinical Gastroenterology, 2008, 42, 862-863.	1.1	37
63	Inducible Nitric Oxide Synthase Inhibitor SD-3651 Reduces Proteinuria in MRL/lpr Mice Deficient in the NOS2 Gene. Journal of Investigative Medicine, 2008, 56, 911-919.	0.7	15
64	Urine Biomarkers Predict the Cause of Glomerular Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 913-922.	3.0	205
65	Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. Arthritis and Rheumatism, 2007, 56, 3738-3747.	6.7	14
66	Response to urinary protein markers in lupus nephritis: The need for concurrent calibration and discrimination statistics in predictive models. Kidney International, 2006, 70, 231-232.	2.6	1
67	The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clinical Immunology, 2006, 121, 243-250.	1.4	74
68	Inducible Nitric Oxide Synthase Inhibitors Reduce Urinary Markers of Systemic Oxidant Stress in Murine Proliferative Lupus Nephritis. Journal of Investigative Medicine, 2005, 53, 347-352.	0.7	25
69	Prediction of urinary protein markers in lupus nephritis. Kidney International, 2005, 68, 2588-2592.	2.6	65
70	Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L190-L201.	1.3	57
71	Curcumin-Induced Apoptosis in Scleroderma Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 28-35.	1.4	86
72	Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. Journal of Investigative Medicine, 2004, 52, 62-71.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. <i>Journal of Investigative Medicine</i> , 2004, 52, 62-71.	0.7	16
74	Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. <i>Journal of Investigative Medicine</i> , 2004, 52, 062.	0.7	8
75	Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans. <i>Journal of Rheumatology</i> , 2003, 30, 60-7.	1.0	36
76	Mediators of injury in lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 498-503.	2.0	44
77	Peroxisome proliferator-activated receptor γ agonists: Potential use for treating chronic inflammatory diseases. <i>Arthritis and Rheumatism</i> , 2002, 46, 598-605.	6.7	30
78	Prostaglandin J2 Inhibition of Mesangial Cell iNOS Expression. <i>Clinical Immunology</i> , 2001, 98, 337-345.	1.4	54
79	Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases. <i>Arthritis and Rheumatism</i> , 2000, 43, 1891-1896.	6.7	142
80	Inhibition of Mesangial Cell Nitric Oxide in MRL/lpr Mice by Prostaglandin J2 and Proliferator Activation Receptor- γ Agonists. <i>Journal of Immunology</i> , 2000, 164, 1498-1504.	0.4	70
81	Prospective Measure of Serum 3-Nitrotyrosine Levels in Systemic Lupus Erythematosus: Correlation with Disease Activity. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 611-621.	2.1	77
82	Effect of Late Modulation of Nitric Oxide Production on Murine Lupus. <i>Clinical Immunology and Immunopathology</i> , 1997, 83, 86-92.	2.1	60